Related posts

This Week’s Stock Picks & BNN Top Picks Summary: BN-T, INTU-Q and 23 Stock Top Picks (Mar 15-21)3 Promising Oversold Stocks3 Best U.S. Healthcare ETFs
Investor Insights

This summary was created by AI, based on 4 opinions in the last 12 months.

Based on the reviews from different experts, Astrazeneca P L C (AZN-N) seems to have a strong focus on cancer drugs, with recent acquisitions targeting rare diseases and vaccine production. The company's strong business model during the Covid-19 pandemic and significant investments in research and development are contributing to its viability for top-line growth. The stock is perceived as a good long-term hold with attractive entry points and a strong line of R&D products.

Consensus
Positive
Valuation
Fair Value
TOP PICK
Astrazeneca P L C

They focus on cancer drugs and making massive inroads. AZN just bought Alexion, which seeks drugs for rare diseases, so the target markets are there. AZN sells at 15x PE with earnings to grow 5-10%. Dividend pays 3.5%. 

(Analysts’ price target is $83.88)
biotechnology / pharmaceutical
TOP PICK
Astrazeneca P L C

Highest growth rate in Pharma sector given current share price. Very attractive entry point (15x earnings). Leader in oncology channels. Chemotherapy products very strong and is a leader in R&D. Good long term hold. 

biotechnology / pharmaceutical
COMMENT
Astrazeneca P L C

The recently bought Ocosavax (a vaccine-maker) and Gracell (an early-stage Chinese biotech working on cancer treatments).

biotechnology / pharmaceutical
PAST TOP PICK
Astrazeneca P L C
(A Top Pick Aug 22/22, Up 13%)

Very strong business model during the Covid-19 pandemic.
Strong line of R&D products.
Huge revision in research providing viability for top line growth.
Current share price presenting good buying opportunity. 
Continues to own shares.

biotechnology / pharmaceutical
COMMENT
Astrazeneca P L C
Believes that company has undergone R & D overhaul. Strong pipeline of new products. One of the best growth stories in the sector. Expecting strong earnings going forward. Current share price is fair.
biotechnology / pharmaceutical
BUY
Astrazeneca P L C
He likes AZN, which is getting approval after approval.
biotechnology / pharmaceutical
DON'T BUY
Astrazeneca P L C
A great pharma with a good stable of products, but he is avoiding all pharma because the new US law will allow Medicare to negotiate prices of drugs, giving them buying power. It's very uncertain how this will effect pharma for 3-6 months at least.
biotechnology / pharmaceutical
BUY
Astrazeneca P L C
Trades around 19x earnings, 2.2% dividend yield. Should have strong revenue and earnings growth due to oncology portfolio. Pipeline is quite good. Should see fruits of refocused portfolio in the next little while. He owns JNJ and NVO.
biotechnology / pharmaceutical
TOP PICK
Astrazeneca P L C
Health care is back in favour, is defensive, and has growth characteristics. AZN has a great pipeline including some drugs that are difficult to make. It trades at an attractive valuation, has a solid balance sheet, good dividend and is liquid. Buy 3, Hold 3, Sell 0. (Analysts’ price target is $72.40)
biotechnology / pharmaceutical
DON'T BUY
Astrazeneca P L C
It's gotten more expensive compared to other drug companies. He won't chase it at these high levels.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Astrazeneca P L C
(A Top Pick Apr 06/21, Up 13.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AZN has triggered its stop at $56. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 21% when combined with the previous recommendation to cover half the position.
biotechnology / pharmaceutical
DON'T BUY
Astrazeneca P L C
They produced an early Covid vaccine, but got lost among other vaccines that were more effective. There are better fish to fry. They report Friday.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Astrazeneca P L C
(A Top Pick Apr 06/21, Up 30%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AZN has achieved its $64 objective. To remain disciplined, we recommend covering half the position here. We continue to recommend holding a stop loss at $56, which if triggered would result in a net investment return over 21% along with today's recommendation of covering half.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Astrazeneca P L C
(A Top Pick Apr 22/21, Up 22.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AZN is progressing well. We now recommend trailing the stop (from $42) to $56. If triggered, this would all but guarantee a net investment return of 13%.
biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Astrazeneca P L C
Stockchase Research Editor: Michael O'Reilly AZN is the COVID-19 vaccine producer that has been granted emergency use authorization in over 50 countries. It also has one of the best pipelines for new biotech drugs. They just acquired a strategic company that will further "boost" their immunology presence. The company pays a good dividend that is projected to have a payout ratio under 75% of cash flow next year. The company is estimated to have added over $2.3 billion to its cash reserves, which are now over $7.5 billion. We would buy this with a stop loss at $42, looking to achieve $64 -- upside potential of 28%. Yield 2.83% (Analysts’ price target is $63.73)
biotechnology / pharmaceutical
Showing 1 to 15 of 33 entries

Astrazeneca P L C(AZN-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Astrazeneca P L C is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Astrazeneca P L C(AZN-N) Frequently Asked Questions

What is Astrazeneca P L C stock symbol?

Astrazeneca P L C is a American stock, trading under the symbol AZN-N on the New York Stock Exchange (AZN). It is usually referred to as NYSE:AZN or AZN-N

Is Astrazeneca P L C a buy or a sell?

In the last year, 1 stock analyst published opinions about AZN-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Astrazeneca P L C.

Is Astrazeneca P L C a good investment or a top pick?

Astrazeneca P L C was recommended as a Top Pick by on . Read the latest stock experts ratings for Astrazeneca P L C.

Why is Astrazeneca P L C stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Astrazeneca P L C worth watching?

1 stock analyst on Stockchase covered Astrazeneca P L C In the last year. It is a trending stock that is worth watching.

What is Astrazeneca P L C stock price?

On 2024-03-28, Astrazeneca P L C (AZN-N) stock closed at a price of $67.92.